UBS Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) but lowers the price target from $25 to $4.
August 16, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Colin Bristow maintains a Buy rating on ALX Oncology Holdings but significantly lowers the price target from $25 to $4.
The significant reduction in the price target from $25 to $4 suggests a negative outlook on the stock's future performance despite the maintained Buy rating. This could lead to a short-term decline in the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100